{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:24:37Z","timestamp":1791919477639,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.berh.2020.101501","type":"journal-article","created":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T16:34:28Z","timestamp":1586018068000},"page":"101501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Allopurinol hypersensitivity: Pathogenesis and prevention"],"prefix":"10.1016","volume":"34","author":[{"given":"Lisa K.","family":"Stamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter T.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2020.101501_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40264-018-0711-x","article-title":"Stevens-johnson syndrome and toxic epidermal necrolysis in association with commonly prescribed drugs in outpatient care other than anti-epileptic drugs and antibiotics: a population-based case-control study","volume":"42","author":"Frey","year":"2019","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.berh.2020.101501_bib2","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/acr.21817","article-title":"Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.berh.2020.101501_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.berh.2020.101501_bib4","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2020.101501_bib5","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40264-013-0084-0","article-title":"Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012","volume":"36","author":"Ramasamy","year":"2013","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.berh.2020.101501_bib6","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.berh.2020.101501_bib7","doi-asserted-by":"crossref","first-page":"709 e1","DOI":"10.1016\/j.jaad.2013.01.032","article-title":"DRESS syndrome: Part II. Management and therapeutics","volume":"68","author":"Husain","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.berh.2020.101501_bib8","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/bmj.331.7517.623","article-title":"Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia","volume":"331","author":"Gutierrez-Macias","year":"2005","journal-title":"Br Med J"},{"key":"10.1016\/j.berh.2020.101501_bib9","first-page":"1361","article-title":"Severe allopurinol hypersensitivity syndrome","volume":"72","author":"Lupton","year":"1979","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.berh.2020.101501_bib10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome: a review","volume":"27","author":"Arellano","year":"1993","journal-title":"Ann Pharmacother"},{"issue":"8","key":"10.1016\/j.berh.2020.101501_bib11","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1136\/annrheumdis-2017-212905","article-title":"Racial\/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study","volume":"77","author":"Keller","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2020.101501_bib12","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B\u22175801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci"},{"issue":"9","key":"10.1016\/j.berh.2020.101501_bib13","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B\u22175801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenetics Genom"},{"issue":"18","key":"10.1016\/j.berh.2020.101501_bib14","article-title":"Association of HLA-B\u22175801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"12","author":"Somkrua","year":"2011","journal-title":"BMC Med Genet"},{"issue":"1","key":"10.1016\/j.berh.2020.101501_bib15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cpt.161","article-title":"Clinical Pharmacogenetics implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update","volume":"99","author":"Saito","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.berh.2020.101501_bib16","first-page":"h4848","article-title":"Use of HLA-B\u221758:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study","volume":"351","author":"Ko","year":"2015","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1016\/j.berh.2020.101501_bib17","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.jaip.2018.11.039","article-title":"The presence of HLA-B75, DR13 homozygosity, or DR14 additionally increases the risk of allopurinol-induced severe cutaneous adverse reactions in HLA-B\u221758:01 carriers","volume":"7","author":"Shim","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Prac"},{"issue":"5","key":"10.1016\/j.berh.2020.101501_bib18","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/all.14174","article-title":"Genetic variants associated with T-cell mediated cutaneous adverse drug reactions: a prisma-compliant systematic review - an EAACI position paper","volume":"75","author":"Oussalah","year":"2020","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.berh.2020.101501_bib19","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"American College of Rheumatology guidelines for the management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricaemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.berh.2020.101501_bib20","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.jaip.2018.12.012","article-title":"Efficacy of the HLA-B\u221758:01 screening test in preventing allopurinol-induced severe cutaneous adverse reactions in patients with chronic renal insufficiency\u2014a prospective study","volume":"7","author":"Park","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.berh.2020.101501_bib21","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/acr.22409","article-title":"Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea","volume":"67","author":"Park","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2020.101501_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094294","article-title":"Cost-effectiveness analysis of HLA-B\u22175801 testing in preventing allopurinol-induced SJS\/TEN in Thai population","volume":"9","author":"Saokaew","year":"2014","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.berh.2020.101501_bib23","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.semarthrit.2016.10.009","article-title":"The cost-effectiveness of HLA-b\u22175801 screening to guide initial urate-lowering therapy for gout in the United States","volume":"46","author":"Jutkowitz","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.berh.2020.101501_bib24","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol","volume":"46","author":"Day","year":"2007","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.berh.2020.101501_bib25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00228-016-2133-y","article-title":"A\u00a0population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis","volume":"73","author":"Wright","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.berh.2020.101501_bib26","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","article-title":"Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin","volume":"74","author":"Chung","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2020.101501_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.berh.2020.101501_bib28","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome. A proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2020.101501_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2020.101501_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kex156","article-title":"The British society for Rheumatology guideline for the management of gout","author":"Hui","year":"2017","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.berh.2020.101501_bib31","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/0091270012439715","article-title":"Clinical Risk Factors for adverse events in allopurinol users","volume":"53","author":"Ryu","year":"2012","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.berh.2020.101501_bib32","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","article-title":"A\u00a0randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2020.101501_bib33","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1136\/annrheumdis-2017-211873","article-title":"Allopurinol dose escalation to achieve serum urate below 6mg\/dl: an open label extension study","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2020.101501_bib34","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jamainternmed.2015.3536","article-title":"Allopurinol use and risk of fatal hypersensitivity reactions; A nationwide population-based study in Taiwan","volume":"175","author":"Yang","year":"2015","journal-title":"JAMA Int Med"},{"issue":"13","key":"10.1016\/j.berh.2020.101501_bib35","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.berh.2020.101501_bib36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40744-019-0143-9","article-title":"Reassessing the safety profile of lesinurad in combination with xanthine oxidase inhibitor therapy","volume":"6","author":"Perez-Ruiz","year":"2019","journal-title":"Rheumatol Ther"},{"issue":"9","key":"10.1016\/j.berh.2020.101501_bib37","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/rheumatology\/kes091","article-title":"Furosemide increases plasma oxypurinol without lowering serum urate \u2013 a complex drug interaction: implications for clinical practice","volume":"51","author":"Stamp","year":"2012","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.berh.2020.101501_bib38","first-page":"842","article-title":"Plasma oxypurinol concentration in a patient with allopurinol hypersensitivity","volume":"16","author":"Puig","year":"1989","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2020.101501_bib39","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/978-1-4684-5673-8_43","article-title":"The allopurinol hypersensitivity syndrome: its relation to plasma oxypurinol levels","volume":"253A","author":"Casas","year":"1989","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.berh.2020.101501_bib40","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/rheumatology\/26.6.445","article-title":"Plasma oxypurinol concentrations during allopurinol therapy","volume":"26","author":"Emmerson","year":"1987","journal-title":"Br J Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2020.101501_bib41","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.2011.113","article-title":"Relationship between serum urate and plasma oxypurinol \u2013 is there a target plasma oxypurinol to achieve serum urate <6mg\/dL?","volume":"90","author":"Stamp","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.berh.2020.101501_bib42","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/cea.12184","article-title":"Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response","volume":"43","author":"Yun","year":"2013","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"10.1016\/j.berh.2020.101501_bib43","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrrheum.2015.132","article-title":"Allopurinol hypersensitivity: investigating the cause and minimizing the risk","volume":"12","author":"Stamp","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"10.1016\/j.berh.2020.101501_bib44","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/gim.2014.195","article-title":"An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing","volume":"17","author":"Jung","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.berh.2020.101501_bib45","doi-asserted-by":"crossref","first-page":"i35","DOI":"10.1093\/rheumatology\/kex422","article-title":"How to prevent allopurinol hypersensitivity reactions?","volume":"57","author":"Stamp","year":"2018","journal-title":"Rheumatology"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694220300188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694220300188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:20:49Z","timestamp":1761499249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694220300188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1521694220300188"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2020.101501","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allopurinol hypersensitivity: Pathogenesis and prevention","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2020.101501","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101501"}}